PEG

China's Booming Industrial Sector Fuels Polyalkylene Glycols Market Growth at 11.6% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Chemicals, Plastics, Manufacturing, PEG, COVID-19, Automotive industry by country, New Normal, Pandemic, PAG, Medical device, Real, Use, Rise, Automotive industry

World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023

Key Points: 
  • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
    World Automobile Production in Million Units: 2008-2022
    How the Automotive Industry was Impacted by the Pandemic & What's the New Normal?
  • Growing Sales of Packaged Foods Present Potential for PAG as Additive: Global Packaged Food Sales in US$ Trillion for 2015, 2017, 2019, 2021 & 2023
    Global PMI Index Points for the Years 2018, 2019 & 2020
    Potential for the Use of PEG in Medical Devices and Materials, Pegylation's Application on the Rise
    PEG and the COVID-19 Vaccine-Related Anaphylactic Reactions: A Review

J.P. Morgan launches Private Markets Fund expanding investor access to private equity investment opportunities

Retrieved on: 
Tuesday, October 10, 2023
JPMorgan Chase, Equity (finance), Investment, PEG, Real assets, Real estate, Growth, Security (finance), Alternatives

NEW YORK, Oct. 10, 2023 /PRNewswire/ -- The Private Equity Group ("PEG") of J.P. Morgan Asset Management today announced the launch of JPMorgan Private Markets Fund ("JPMF"), a 1940 Act-registered, evergreen private equity fund. JPMF is designed to provide access to private equity investments for qualified and accredited individual and institutional clients1. JPMF's features include a low $25,000 investment minimum2, no capital calls, simplified tax reporting and potential for quarterly liquidity3. JPMF is currently available on select private bank and custodial platforms and will expand availability in 2024. 

Key Points: 
  • NEW YORK, Oct. 10, 2023 /PRNewswire/ -- The Private Equity Group ("PEG") of J.P. Morgan Asset Management today announced the launch of JPMorgan Private Markets Fund (" JPMF "), a 1940 Act-registered, evergreen private equity fund.
  • JPMF is designed to provide access to private equity investments for qualified and accredited individual and institutional clients1.
  • "Private equity has traditionally been difficult for individuals to access, so we're thrilled to deliver our institutional-grade private equity investment expertise to this investor base through JPMF."
  • "We are witnessing increased demand from all investor types to look beyond public markets for access to compelling private company investment opportunities, and the launch of JPMF is an important step in expanding access to the potential long-term return and volatility benefits of private equity," said Ashmi Mehrotra, Co-Head of PEG at J.P. Morgan Asset Management.

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

Retrieved on: 
Tuesday, September 26, 2023
Cosmetics, Retail, Health, Other Health, Specialty, General Health, Optical, Cream, Paraben, Serum, Sulfate, Nicotinamide, Biotin, PHMB, Eye, EYE, Ophthalmology, PEG, Hyaluronic acid, Caffeine, Prostaglandin, Bausch & Lomb, Dermatology, Mineral oil, Patient, Peptide, Consumer, NYSE, Safety, Telescopic sight

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY EYE ILLUMINATIONS , a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye area.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY EYE ILLUMINATIONS , a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye area.
  • “Many products contain chemicals or preservatives that can irritate the delicate area of and around the eye,” said John Ferris, executive vice president, Consumer, Bausch + Lomb.
  • LUMIFY EYE ILLUMINATIONS Hydra-Gel Brightening Eye Cream – a unique blend of optic brighteners and firming ingredients helps skin look brighter and smoother with a subtle glow.
  • “LUMIFY EYE ILLUMINATIONS was developed specifically for the sensitive eye area with extensive safety and performance testing.

Definitive Healthcare Welcomes Scott Stephenson to Board of Directors

Retrieved on: 
Friday, September 8, 2023
Boston Consulting Group, Data set, VRSK, Software as a service, IPO, Stephenson, Verisk Analytics, University, Atlas, PEG, Intelligence, Scott, Gas, Spectrum Equity, Harvard Business School, PSE, NYSE, Management

FRAMINGHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors.

Key Points: 
  • FRAMINGHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (Nasdaq: DH ), an industry leader in healthcare commercial intelligence, today announced two changes to its Board of Directors.
  • On September 6, 2023, Scott Stephenson, the former Chief Executive Officer of Verisk Analytics, joined the Board of Directors and the nominating and corporate governance committee of the Board, while Chris Mitchell, managing director of Spectrum Equity, stepped down from the Board of Directors.
  • “We are thrilled to welcome Scott Stephenson to the Definitive Healthcare Board of Directors,” said Jason Krantz, Executive Chairman of the Board and founder of Definitive Healthcare.
  • “I’m excited to join the Definitive Healthcare Board of Directors,” said Stephenson.

Perricone MD Introduces New Hypoallergenic Clean Correction Collection

Retrieved on: 
Monday, August 7, 2023
Cream, Elasticity, Nicotinamide, Paraben, Collection, Sulfate, Propylene glycol, Ageing, PEG, Woman, Silicone, BHT, Trial of the century, Formaldehyde, SAN, Water, CBD, BHA, Allergen, Ceramide, Skin, Peptide, Cosmetics, Birth control

SAN FRANCISCO, Aug. 7, 2023 /PRNewswire/ -- Perricone MD continues its dedication to breakthrough skincare solutions with the launch of the Hypoallergenic Clean Correction Collection. This revolutionary clean regimen was specifically formulated with a Three-Tier approach to soothe, protect and correct the most sensitive skin. The collection includes gentle, yet highly effective formulas, specifically developed with science-backed strength to deliver unparalleled results.

Key Points: 
  • SAN FRANCISCO, Aug. 7, 2023 /PRNewswire/ -- Perricone MD continues its dedication to breakthrough skincare solutions with the launch of the Hypoallergenic Clean Correction Collection.
  • Inspired by our foundational and innovative Three-Tier philosophy, the Hypoallergenic Clean Correction Collection is a game-changer for sensitive skin.
  • The entire Hypoallergenic Clean Correction Collection has been awarded the National Psoriasis Foundation Seal of Recognition marking these products as safe for those with sensitive skin.
  • Formulated with the power of Perricone MD and reinforced by a clean positioning, sensitive skin consumers will never have to compromise on their skincare routine again."

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous Infusion Formulation

Retrieved on: 
Thursday, July 20, 2023
Volunteering, Male, Regulation of therapeutic goods, Urinary tract infection, UTI, Respiratory rate, Infection, Kidney failure, Pharmacokinetics, ECG, PEG, Therapeutic Goods Administration, ASX, Escherichia coli, FSE, Toxicity, ATCC, Kidney, Gram-negative bacteria, Female, Sepsis, Șaeș, Thermoregulation, Death, Vital signs, MD, Patient, Bacteria, Heart rate, Health, Plasma (physics), Monitoring, Safety, RCE, Medical imaging, Pharmaceutical industry, Dietary supplement, Medical device, Phosphorus, Urine, Plasma

SYDNEY Australia, July 20, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I (R327-001) study of RECCE® 327 (R327) as an intravenous (IV) infusion formulation in 80 healthy male subjects.

Key Points: 
  • We look forward to building off these results by initiating a Phase II study in patients with early-stage sepsis.
  • A total of 80 subjects were randomized in eight single-dose cohorts, and 60 subjects received R327, with 20 receiving placebo.
  • Enrolled subjects completed dosing per the protocol and completed the trial without dosing interruptions.
  • The Company is currently conducting a Phase I/II UTI clinical trial evaluating R327 IV at faster infusion rates – recently announcing its first cohort dosed, including its first female subject.

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

Retrieved on: 
Saturday, June 24, 2023
Learning, Auckland City Hospital, Viremia, University, Conditional sentence, Safety, NRTI, HDV, Clinical trial, Pharmacokinetics, PEG, Hepatitis B, Small RNA, Congress, Hong Kong, Spectrochimica Acta Part B, Hepatology, Patient, European Association for the Study of the Liver, Division, SAN, Clinical research, Poster, HBV, Vaccine, Tea, Medical device, Pharmaceutical industry, Health insurance, Medicine, HBsAg, Gastroenterology

SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B and D virus (HBV and HDV) portfolio that were presented at the EASL™ (European Association for the Study of the Liver) Congress.

Key Points: 
  • These data further support the clinical development of these investigational medicines for the treatment of HDV.
  • “I am very excited by the progress we are making toward our goal of achieving HBV functional cure.
  • Our data to-date with VIR-2218 and PEG-IFN-⍺ support our hypothesis of using a cocktail of antivirals combined with immunomodulators.
  • The majority of adverse events were consistent with the known effects of PEG-IFN-⍺ and resolved after the end of treatment.

PSE&G's Energy Efficiency Programs Expected to Lead to Approximately $300 Million Saved and Over One Million Metric Tons of Carbon Dioxide Emissions Reduced/Avoided Annually

Retrieved on: 
Wednesday, June 14, 2023
New Jersey Board of Public Utilities, U.S. Department of Energy, Office of Inspector General, J.D. Power, Ernst & Young Entrepreneur of the Year Award, Edison Electric Institute, Dow Jones, Electricity, PSEG, Public, PSE&G, PEG, Public utility, Recycling, Carbon, Organization, Gas, EPA, LED, Climate change, Partner, Clean Energy Act 2011, Natural gas, PSE, Acquire, BPU, Mid-Atlantic (United States), NYSE, EnergySolutions, Renewable energy

NEWARK, N.J., June 14, 2023 /PRNewswire/ -- In its first 30 months since implementation close to 1.7 million customers have received services from PSE&G's award winning energy efficiency programs, including approximately 300,000 customers who took action to save energy through these programs. Through their participation in these programs, customers are expected to save approximately $300 million1 on their utility bills annually. These savings are the result of many program activities, including recycling over 16,000 appliances, delivering over 11 million high-efficiency LED lightbulbs and completing over 53,000 home energy audits from the program's implementation through March 2023.

Key Points: 
  • Through their participation in these programs, customers are expected to save approximately $300 million1 on their utility bills annually.
  • Participating natural gas customers are expected to save a total of approximately 35 million therms of natural gas per year.
  • PSE&G's programs allow residential customers to receive discounts on high efficiency products and energy efficient equipment and services, including free home energy assessments.
  • For more information on PSE&G's energy efficiency programs including how to sign up, visit homeenergy.pseg.com for residential customers or bizsave.pseg.com for business customers.

PILOT PROJECT LAUNCHES 30 FREE PUBLIC SUNSCREEN DISPENSERS IN MUNICIPALITIES ACROSS CANADA

Retrieved on: 
Thursday, June 1, 2023
Perfume, Zinc, Canadian National Exhibition Association Act, Zinc oxide, Skin cancer, AB, PEG, SPF, Brooks, Alberta, YMCA Hotel (Chicago, Illinois), Incidence, City, Swimming, Risk, Cancer, Health Canada, Allergen, Cosmetics, Grand Bay-Westfield, NB, Penticton, Westlock

TORONTO, June 1, 2023 /CNW/ - This summer, 30 additional public sunscreen dispensers are coming to locations across Canada as part of a pilot project to fight skin cancer by making sunscreen more accessible.

Key Points: 
  • TORONTO, June 1, 2023 /CNW/ - This summer, 30 additional public sunscreen dispensers are coming to locations across Canada as part of a pilot project to fight skin cancer by making sunscreen more accessible.
  • This summer, 30 sunscreen dispensers are coming to locations across Canada as part of a project to fight skin cancer.
  • Last year, the municipalities of Riverview, NB, Summerside, PEI, Brooks, AB, and New Westminster, BC installed dispensers as part of the project.
  • The dispensers are automatic and touchless, and provide free, Health Canada approved SPF 30 sunscreen for anyone who needs it.